Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Repurposing drugs for disease modification in multiple sclerosis
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
Regenerative cellular therapies for neurologic diseases.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Information for healthcare professionals: Rituximab
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

Pages